Skip to Content

Early responses for BCMA-directed CAR-T cell therapy in progressive MM after 1-3 prior lines of therapy

Mounzer Agha, director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center, present data from CARTITUDE-2 study for patients with Multiple Myeloma, who had received 1–3 prior lines of therapy. In the CARTITUDE-2 study, the patients were treated with Ciltacabtagene autoleucel – a chimeric antigen receptor T (CAR-T) cell therapy expressing two B-cell maturation antigen (BCMA)-targeting, single-domain antibodies designed to confer avidity.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top